|
|
| The present Competitive Intelligence Report about MEK Inhibitors provides a competitor evaluation in the field of synthetic molecules targeting MEK pathway for treatment of cancer as of June 2009.
The mitogen activated protein kinases (MAPKs) are conserved proteins that regulate cell growth, division and death. Although activated in the cytosol, the MAPKs translocate to the nucleus upon activation and phosphorylate a large number of nuclear proteins. Investigating how Ras transmits extracellular growth signals, the MAPK pathway has emerged as the crucial route between membrane-bound Ras and the nucleus. The MAPK pathway represents a cascade of phosphorylation events including three pivotal kinases, namely Raf, MEK (MAP kinase kinase), and ERK (MAP kinase). The report includes a compilation of current active projects in research and development of synthetic molecules targeting the Mitogen-activated ERK kinase (MEK) pathway. In addition, the report lists company-specific R&D pipelines of MEK targeting molecules. Competitor projects are listed in a tabular format providing information on:
|
Related Markets
- Biotechnology
- General Biotechnology
- Pharmaceuticals
- Research & Development
- Drug Discovery
- Therapeutic Area
- Oncology/Hematology
Oncology/Hematology Reports
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Peptides
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Angiogenesis and Protein Kinase Inhibitors
